Search research articles
Contact Us
Filters
Showing results (351-360 of 401) with videos related to
Page
of 41
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
The Journal of Clinical Investigation
|
June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Justin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A Drilon, G Li, S Dogan, et al.
Cancer Discovery
|
March 17, 2019
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven Cancer
Emily K Slotkin, Daniel Diolaiti, Neerav N Shukla, et al.
Scientific Reports
|
January 20, 2024
High dimensional predictions of suicide risk in 4.2 million US Veterans using ensemble transfer learning
Sayera Dhaubhadel, Kumkum Ganguly, Ruy M Ribeiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T Li, Ronglai Shen, Darren Buonocore, et al.
NPJ Breast Cancer
|
April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Lillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Nature Medicine
|
August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Emiliano Cocco, Alison M Schram, Amanda Kulick, et al.
Page
of 41
Search research articles
Search
Showing results (351-360 of 401) with videos related to
Sort By:
Page
of 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
The Journal of Clinical Investigation
|
June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Justin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A Drilon, G Li, S Dogan, et al.
Cancer Discovery
|
March 17, 2019
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven Cancer
Emily K Slotkin, Daniel Diolaiti, Neerav N Shukla, et al.
Scientific Reports
|
January 20, 2024
High dimensional predictions of suicide risk in 4.2 million US Veterans using ensemble transfer learning
Sayera Dhaubhadel, Kumkum Ganguly, Ruy M Ribeiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T Li, Ronglai Shen, Darren Buonocore, et al.
NPJ Breast Cancer
|
April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Lillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Nature Medicine
|
August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Emiliano Cocco, Alison M Schram, Amanda Kulick, et al.
Page
of 41